Nasus Pharma

Company Overview

Snapshot

Founded in May 2019 by Udi Gilboa and Dr. Dalia Meggido, Nasus Pharma operates with 1–10 employees. The company has raised $25 million across two funding rounds. In August 2025, Nasus Pharma completed its Initial Public Offering and listed on the NYSE.

Business overview

Nasus Pharma is a clinical-stage biopharmaceutical company specializing in the development of needle-free, powder-based intranasal products. The company's core technology focuses on microsphere-based formulations designed to assist patients in acute emergency situations, such as opioid overdose and anaphylactic shock. Nasus Pharma's portfolio includes programs for intranasal naloxone (NS-001) and intranasal epinephrine (NS-002), targeting the Health Tech &.

Strategic signal

In March 2026, Nasus Pharma announced positive top-line data from its Phase 2 clinical study of NS002 Intranasal Epinephrine Powder, demonstrating significantly superior and faster epinephrine delivery compared to EpiPen® with an accelerated speed to therapeutic threshold. This development is a strong validation of the company's core technology and its potential to address critical emergency medical needs, signaling to investors a clear advancement towards pivotal studies and commercialization in the biopharmaceutical market.

Company Intelligence Q&A

When did Nasus Pharma go public?

Nasus Pharma completed its Initial Public Offering and listed on the NYSE in August 2025.

What was the most recent funding event for Nasus Pharma?

In February 2026, Nasus Pharma announced the closing of a $15.0 million private placement.

What is the status of Nasus Pharma's NS002 Intranasal Epinephrine Powder program?

In March 2026, Nasus Pharma announced positive top-line data from its Phase 2 clinical study of NS002, demonstrating significantly superior and faster epinephrine delivery compared to EpiPen®.

Has Nasus Pharma expanded any agreements recently?

In October 2025, Nasus Pharma announced an expanded agreement to support the development and commercialization of its NS002 Intranasal Epinephrine Program.

What is the latest news regarding Nasus Pharma's preclinical studies?

In June 2026, Nasus Pharma announced positive results from a preclinical pharmacokinetic and safety study of Intranasal Ondansetron (NS003).